The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL OMB 3235-Number: 0076 Estimated average burden hours per 4.00 response:

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	None	Entity Type
0001401914		naceuticals Inc	X Corporation
Name of Issuer	Tempernum		Limited Partnership
Cerulean Pharma Inc.			Limited Liability Company
Jurisdiction of			General Partnership
Incorporation/Organization	1		Business Trust
DELAWARE			Other (Specify)
Year of Incorporation/Or	rganization		
Over Five Years Ago			
X Within Last Five Years (Specify	Year) 2005		
Yet to Be Formed			
2. Principal Place of Business and C	ontact Information		
Name of Issue	er		
Cerulean Pharma Inc.			
Street Address	s 1	St	reet Address 2
840 Memorial Drive		5th Floor	
City Stat	e/Province/Country	ZIP/PostalCode	Phone Number of Issuer
Cambridge MASS	SACHUSETTS	02139	617-551-9600
3. Related Persons			
Last Name	First	t Name	Middle Name
Fetzer	Oliver		
Street Address 1	Street A	Address 2	
840 Memorial Drive	5th Floor		
City	State/Provi	ince/Country	ZIP/PostalCode
Cambridge	MASSACHUSET	TS 021	39
Cambridge Relationship: X Executive Officer			39
-	X Director Promote		39
Relationship: X Executive Officer	X Director Promote ary):		39 Middle Name
Relationship: X Executive Officer Clarification of Response (if Necess	X Director Promote ary):	r	
Relationship: X Executive Officer Clarification of Response (if Necess Last Name	X Director Promote ary): First Alexandra	r	
Relationship: X Executive Officer Clarification of Response (if Necess Last Name Glucksmann	X Director Promote ary): First Alexandra	er t Name	
Relationship: X Executive Officer Clarification of Response (if Necess Last Name Glucksmann Street Address 1	X Director Promote ary): First Alexandra Street A 5th Floor	er t Name	

Clarification of Response (if Necessary):

Relationship: X Executive Officer Director Promoter

Last Name	First Name	Middle Name
Roberts	Bryan	E.
Street Address 1	Street Address 2	
840 Memorial Drive	5th Floor	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139
Relationship: Executive Officer S	X Director Promoter	
Clarification of Response (if Necessa	nry):	
Last Name	First Name	Middle Name
Crane	Alan	
Street Address 1	Street Address 2	
840 Memorial Drive	5th Floor	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139
Relationship: Executive Officer <i>Y</i>	X Director Promoter	
Clarification of Response (if Necessa	ıry):	
Last Name	First Name	Middle Name
Sasisekharan	Ram	
Street Address 1	Street Address 2	
840 Memorial Drive	5th Floor	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139
Relationship: Executive Officer X	C Director Promoter	
Clarification of Response (if Necessa	ury):	
Last Name	First Name	Middle Name
Langer	Robert	
Street Address 1	Street Address 2	
840 Memorial Drive	5th Floor	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139
Relationship: Executive Officer 2	C Director Promoter	
Clarification of Response (if Necessa	ury):	
Last Name	First Name	Middle Name
Tepper	Robert	
Street Address 1	Street Address 2	
840 Memorial Drive	5th Floor	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139
Relationship: Executive Officer 2	X Director Promoter	
Clarification of Response (if Necessa	ury):	
Last Name	First Name	Middle Name
Silveri	Jean	
Street Address 1	Street Address 2	
840 Memorial Drive	5th Floor	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Roberts	Karen	
Street Address 1	Street Address 2	
840 Memorial Drive	5th Floor	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139
Relationship: X Executive Officer	Director Promoter	

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company	Health Care Biotechnology Health Insurance Hospitals & Physicians X Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial	Retailing Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports
Act of 1940? Yes No Other Banking & Financial Servic Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy	Construction	Lodging & Conventions Tourism & Travel Services Other Travel Other
5. Issuer Size Revenue Range OR	A	Aggregate Net Asset Value Range

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))

Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	X Rule 506 Securities Act Investment Co	Section 4(5) Section 3(c)	
	Section 3(c)(1		9)
	Section $3(c)(2$		
	Section 3(c)(3		
	Section 3(c)(4	Section 3(c)	12)
	Section 3(c)(5	5) Section 3(c)(13)
	Section 3(c)(6	5) Section 3(c)(1	14)
	Section 3(c)(7))	
7. Type of Filing			
X New Notice Date of First Sale 2010-09-29 Amendment	First Sale Yet to C	Decur	
8. Duration of Offering			
Does the Issuer intend this offering to last more	than one year?	Yes X No	
9. Type(s) of Securities Offered (select all that a	pply)		
Equity		Pooled Investment Fund	
X Debt X Option, Warrant or Other Right to Acquire A	nother Security	Tenant-in-Common Secu Mineral Property Securit	
Security to be Acquired Upon Exercise of Op Other Right to Acquire Security	•	Other (describe)	
10. Business Combination Transaction			
Is this offering being made in connection with a a merger, acquisition or exchange offer?	business combinat	ion transaction, such as	Yes X No
Clarification of Response (if Necessary):			
11. Minimum Investment			
Minimum investment accepted from any outside	e investor \$0 USD		
12. Sales Compensation			
Recipient	Recipie	ent CRD Number X None	3
(Associated) Broker or Dealer X None	(Assoc	iated) Broker or Dealer C	RD Number X None
Street Address 1		Street Addres	
City State(s) of Solicitation (select all that apply) Check "All States" or check individual States		rovince/Country gn/non-US	ZIP/Postal Code
13. Offering and Sales Amounts			
Total Offering Amount \$1,499,999 USD o	r Indefinite		
Total Amount Sold\$1,499,999 USDTotal Amount Sold\$1,499,999 USD	i indefinite		
Total Remaining to be Sold\$0 USD o	r Indefinite		
Clarification of Response (if Necessary):			
14. Investors			

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Cerulean Pharma Inc.	/s/ Jean Silveri	Jean Silveri	Senior Vice President, General Counsel and Secretary	2010-10-12

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this

15

undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.